In vitro and in vivo activity of a recombinant toxin, OLX-209, which targets the erbB-2 oncoprotein.
OLX-209 has readily measurable activity, is safe in experimental animals, and is efficacious in model systems. These results support the concept of OLX-209 and provide groundwork for further development of this oncoprotein targeted agent.
Fischer
P H
PH
Oncologix Inc., Gaithersburg, MD 20878.
Bird
R E
RE
Kasprzyk
P G
PG
King
C R
CR
Turner
N A
NA
Pastan
I
I
Kihara
A
A
Batra
J
J
D036002:ADP Ribose Transferases; D000818:Animals; D000906:Antibodies; D001427:Bacterial Toxins; D001943:Breast Neoplasms / Q000737:chemistry; D015195:Drug Design; D005069:Evaluation Studies as Topic; D005098:Exotoxins / Q000008:administration & dosage* / Q000235:genetics / Q000494:pharmacology; D006801:Humans; D000922:Immunotoxins / Q000008:administration & dosage* / Q000494:pharmacology / Q000633:toxicity; D051379:Mice; D008819:Mice, Nude; D009374:Neoplasms, Experimental / Q000188:drug therapy; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000187:drug effects*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage* / Q000494:pharmacology / Q000633:toxicity; D011994:Recombinant Proteins / Q000494:pharmacology; D057127:Single-Chain Antibodies; D013274:Stomach Neoplasms / Q000188:drug therapy; D014407:Tumor Cells, Cultured; D037521:Virulence Factors; D000097668:Pseudomonas aeruginosa Exotoxin A
D036002:ADP Ribose Transferases; D000906:Antibodies; D001427:Bacterial Toxins; D005098:Exotoxins; D000922:Immunotoxins; D018719:Erb-b2 Receptor Tyrosine Kinases; D011993:Recombinant Fusion Proteins; D011994:Recombinant Proteins; D057127:Single-Chain Antibodies; D037521:Virulence Factors; D000097668:Pseudomonas aeruginosa Exotoxin A; C089922:OLX 209